Drugs

Rhone-Poulenc Rorer's Menorest(R) Receives Regulatory Approval in Multiple Markets

Strategic Insights

Oct 18, 1995 — 1 min read

Menorest(R), a transdermal 17-beta estradiol treatment for postmenopausal symptoms, has secured regulatory approval in Italy, Spain, Denmark, Ireland, South Africa, and New Zealand. The patch-based system, developed by Noven Pharmaceuticals, utilizes matrix technology to deliver 17-beta estradiol through the skin and into the bloodstream. With this approval, Menorest(R) has now been approved in 13 countries, solidifying its position as a leading treatment for menopausal symptoms and osteoporosis.

Key Takeaways:

Menorest(R) has received regulatory approval in 13 countries, including Italy, Spain, Denmark, Ireland, South Africa, and New Zealand.
The patch-based system utilizes matrix technology, which functions as both the drug platform and the means of affixing the system to the patient's skin.
Menorest(R) is designed in dosage strengths of 37.5, 50, 75, and 100 micrograms per day and delivers 17-beta estradiol through the skin and into the bloodstream continuously for three to four days.
Noven Pharmaceuticals, the innovator of the matrix technology used for Menorest(R), is committed to becoming a fully integrated pharmaceutical company capable of developing, manufacturing, and marketing pharmaceutical products that incorporate alternate drug delivery technologies.
Rhone-Poulenc Rorer, the marketer of Menorest(R), invested more than $600 million in research and development in 1994.
Menorest(R) has previously received regulatory approvals in The Netherlands, France, Finland, Sweden, Luxembourg, Australia, and The United Kingdom.

Statistics:

Over 60 million women in Europe are in the menopausal age range.
Menorest(R) has received regulatory approval in 13 countries, including Italy, Spain, Denmark, Ireland, South Africa, and New Zealand.
Rhone-Poulenc Rorer invested more than $600 million in research and development in 1994.

Sources:

PRNewswire press release, October 19, 1995
Noven Pharmaceuticals, Inc. (Nasdaq: NOVN)
Rhone-Poulenc Rorer (NYSE: RPR)

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients